Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface. Treatment of AL amyloidosis is based on the elimination of the plasma cell clone. The combination of cyclophosphamide–bor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Foteini Theodorakakou, Meletios A. Dimopoulos, Efstathios Kastritis
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/b193029987d6402aaadfdebb29ef976c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b193029987d6402aaadfdebb29ef976c
record_format	dspace
spelling	oai:doaj.org-article:b193029987d6402aaadfdebb29ef976c2021-11-23T23:03:29ZDaratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis2040-621510.1177/20406207211058334https://doaj.org/article/b193029987d6402aaadfdebb29ef976c2021-11-01T00:00:00Zhttps://doi.org/10.1177/20406207211058334https://doaj.org/toc/2040-6215Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface. Treatment of AL amyloidosis is based on the elimination of the plasma cell clone. The combination of cyclophosphamide–bortezomib–dexamethasone (CyBorD) is the most widely used and is considered a standard of care; however, complete hematologic response rates and organ response rates remain unsatisfactory. Daratumumab, an anti-CD38 monoclonal antibody, has demonstrated encouraging results, with rapid and deep responses, in patients with relapsed or refractory AL amyloidosis as monotherapy with a favorable toxicity profile. The large phase-III, randomized, ANDROMEDA study evaluated the addition of daratumumab to CyBorD in previously untreated patients with AL amyloidosis and demonstrated that addition of daratumumab can substantially improve hematologic complete response rates, survival free from major organ deterioration or hematologic progression, and organ responses. In this review, we discuss the role of daratumumab in the treatment of AL amyloidosis, its mechanism of action, and the results of ANDROMEDA study that led to the first approved therapy for AL amyloidosis.Foteini TheodorakakouMeletios A. DimopoulosEfstathios KastritisSAGE PublishingarticleDiseases of the blood and blood-forming organsRC633-647.5ENTherapeutic Advances in Hematology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Foteini Theodorakakou Meletios A. Dimopoulos Efstathios Kastritis Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
description	Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface. Treatment of AL amyloidosis is based on the elimination of the plasma cell clone. The combination of cyclophosphamide–bortezomib–dexamethasone (CyBorD) is the most widely used and is considered a standard of care; however, complete hematologic response rates and organ response rates remain unsatisfactory. Daratumumab, an anti-CD38 monoclonal antibody, has demonstrated encouraging results, with rapid and deep responses, in patients with relapsed or refractory AL amyloidosis as monotherapy with a favorable toxicity profile. The large phase-III, randomized, ANDROMEDA study evaluated the addition of daratumumab to CyBorD in previously untreated patients with AL amyloidosis and demonstrated that addition of daratumumab can substantially improve hematologic complete response rates, survival free from major organ deterioration or hematologic progression, and organ responses. In this review, we discuss the role of daratumumab in the treatment of AL amyloidosis, its mechanism of action, and the results of ANDROMEDA study that led to the first approved therapy for AL amyloidosis.
format	article
author	Foteini Theodorakakou Meletios A. Dimopoulos Efstathios Kastritis
author_facet	Foteini Theodorakakou Meletios A. Dimopoulos Efstathios Kastritis
author_sort	Foteini Theodorakakou
title	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
title_short	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
title_full	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
title_fullStr	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
title_full_unstemmed	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
title_sort	daratumumab plus cybord for patients with newly diagnosed light chain (al) amyloidosis
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/b193029987d6402aaadfdebb29ef976c
work_keys_str_mv	AT foteinitheodorakakou daratumumabpluscybordforpatientswithnewlydiagnosedlightchainalamyloidosis AT meletiosadimopoulos daratumumabpluscybordforpatientswithnewlydiagnosedlightchainalamyloidosis AT efstathioskastritis daratumumabpluscybordforpatientswithnewlydiagnosedlightchainalamyloidosis
_version_	1718416115207503872

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

Ejemplares similares